What Ruxandra Teslo thinks about Psychotherapy
Geneticist by training and writer on science, medicine and policy. She holds a PhD in genomics, writes at Ruxandra's Substack and for Works in Progress, and co-founded Clinical Trial Abundance, a project arguing that the binding constraint on new medicines is how trials are run rather than how drugs are designed.
Ruxandra Teslo did not write this page.
We collected these quotes from things they published elsewhere, and every quote links to where it was said. They have no account here and have not endorsed this site. Quotes are word for word; the short line under each one is our own restatement, not their wording. Their own site. Is this you? Claim it or ask us to remove it. Or tell us what is wrong here.
Filter Psychotherapy · Newest first
Only Ruxandra Teslo on Psychotherapy. See everyone on Psychotherapy
1 dated position, 2026, in their own words. Our reading of what Ruxandra Teslo has said — not written or endorsed by them.
-
Their wordsLastly, the duration of a clinical trial does not merely determine how fast an individual therapy reaches patients. It also shapes which diseases attract serious investment and which do not.
↗A response to Dario Amodei on AI & clinical trialswritingruxandrabio.com 4th of 5 in this piece